

Celeste Lebbe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5198160/celeste-lebbe-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170
papers

36,050
citations

40
h-index

183
g-index

183
ext. papers

43,457
ext. citations

8.3
avg, IF

6.38
L-index

#	Paper	IF	Citations
170	Sample CME Manuscript Submission - Response to Pham et al. "Review BRAF inhibition and the spectrum of granulomatous reactions".. <i>Journal of the American Academy of Dermatology</i> , 2022 ,	4.5	0
169	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy.. <i>Cancer Cell</i> , 2022 , 40, 450-451	24.3	0
168	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
167	545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201) 2021 , 9, A574-A575		0
166	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
165	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 765608	5.3	1
164	MAPK blockade, toxicities, pathogenesis and management. <i>Current Opinion in Oncology</i> , 2021 , 33, 139-145	4.2	0
163	Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data. <i>Current Opinion in Oncology</i> , 2021 , 33, 127-132	4.2	2
162	Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021 , 105, 67-78	1.8	5
161	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 147, 170-181	7.5	11
160	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 761-769.e2	4.3	3
159	Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9533-9533	2.2	
158	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
157	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders 2021 , 9,		4
156	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9516-9516	2.2	6
155	Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9543-9543	2.2	1
154	Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21545-e21545	2.2	1

153	Impact of surgical margins on survival in cutaneous sarcomas: A nationwide study of French Sarcoma Group (FSG) from NETSARC Database.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e23537-e23537	2.2	
152	Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. <i>Clinical Cancer Research</i> , 2021 , 27, 3876-3883	12.9	4
151	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	0
150	Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans. <i>Cancers</i> , 2021 , 13,	6.6	1
149	Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	3
148	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021 , 11, 672021	5.3	1
147	SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). <i>European Journal of Cancer</i> , 2021 , 148, 121-123	7.5	8
146	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 836-847	21.7	33
145	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
144	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study 2021 , 9,		9
143	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2021 , 16, 37-46	5	3
142	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021 , 16, 47-57	5	4
141	Successful rechallenge with avelumab in Merkel cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 153, 96-97	7.5	
140	Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database. <i>Immunotherapy</i> , 2021 , 13, 905-916	3.8	
139	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. <i>Lancet Oncology, The</i> , 2021 , 22, e343-e344	21.7	0
138	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. <i>Science Advances</i> , 2021 , 7,	14.3	11
137	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021 , 34, 2154-2165	3	
136	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program 2020 , 8,		29

135	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial 2020 , 8,		70
134	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
133	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020 , 13, 457-467	3.7	3
132	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e29-e30	8.9	1
131	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020 , 12,	6.6	10
130	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020 , 128, 60-82	7.5	60
129	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020 , 128, 83-102	7.5	76
128	Deep cutaneous fungal infections in solid-organ transplant recipients. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 455-462	4.5	5
127	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
126	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10005-10005	2.2	17
125	The nature and management of acquired resistance to PD1-based therapy in melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10014-10014	2.2	3
124	The antiPD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600E mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10028-10028	2.2	7
123	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10031-10031	2.2	3
122	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10034-10034	2.2	1
121	Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10057-10057	2.2	3
120	The antiPD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 57-57	2.2	3
119	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 39-39	2.2	
118	Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10026-10026	2.2	1

117	Quality-of-life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020 , 126, 611-618	6.4	4
116	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2020 , 13, 275-286	4.9	6
115	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. <i>Current Opinion in Oncology</i> , 2020 , 32, 79-84	4.2	14
114	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020 , 125, 114-120	7.5	29
113	Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. <i>Cancers</i> , 2020 , 12,	6.6	14
112	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3937-3946	2.2	39
111	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020 , 215, 1539-1548	5.4	9
110	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
109	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 5102-5112	12.9	7
108	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020 , 12,	6.6	12
107	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients 2020 , 8,		11
106	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020 , 16, 2089-2099	3.6	1
105	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. <i>Cancers</i> , 2020 , 12,	6.6	5
104	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2476-2487	2.2	72
103	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
102	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 448-455	4.5	16
101	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
100	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019 , 155, 673-678	5.1	5

99	Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. <i>European Journal of Cancer</i> , 2019 , 113, 72-74	7.5	6
98	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019 , 112, 38-46	7.5	24
97	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
96	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 867-875	2.2	135
95	Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin. <i>Dermatology and Therapy</i> , 2019 , 9, 383-388	4	7
94	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 609-618	7.4	18
93	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e82	2.4	22
92	Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1263-1272	21.7	69
91	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2512-2512	2.2	13
90	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9515-9515	2.2	1
89	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9531-9531	2.2	26
88	Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9545-9545	2.2	2
87	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3159-TPS3159	2.2	
86	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e21021-e21021	2.2	
85	New perspectives in Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2019 , 31, 72-83	4.2	8
84	CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. <i>Cancers</i> , 2019 , 11,	6.6	42
83	Severe gastrointestinal toxicity of MEK inhibitors. <i>Melanoma Research</i> , 2019 , 29, 556-559	3.3	6
82	Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review. <i>Transplantation</i> , 2019 , 103, e22-e28	1.8	8

81	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 209-222	3.5	12
80	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , 2019 , 5, 187-194	13.4	173
79	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e129	2.4	24
78	Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study. <i>Psycho-Oncology</i> , 2018 , 27, 1861-1864	3.9	6
77	Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 945-947	4.5	4
76	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018 , 93, 147-149	7.5	8
75	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e180077	13.4	214
74	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1-year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial 2018 , 6, 7		191
73	Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. <i>Journal of Hepatology</i> , 2018 , 69, 548-550	13.4	36
72	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018 , 18, 3065-3071	8.7	27
71	DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11501-11501	2.2	6
70	A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11557-11557	2.2	3
69	Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9505-9505	2.2	27
68	Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9520-9520	2.2	3
67	Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9537-9537	2.3	5
66	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. <i>European Journal of Dermatology</i> , 2018 , 28, 736-749	0.8	3
65	EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma. <i>Oncotarget</i> , 2018 , 9, 8478-8488	3.3	4
64	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18609-e18609	2.2	

63	Elderly patients' tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21536-e21536	2.2	
62	Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1197-1208	7.4	17
61	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 226-235	2.2	302
60	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 393-403	21.7	69
59	Recurring seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 281-287	5.3	32
58	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
57	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 863-873	21.7	389
56	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 611-622	21.7	306
55	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017 , 71, 53-69	7.5	217
54	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17077	51.1	219
53	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 115-124	7.5	49
52	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. <i>Melanoma Research</i> , 2017 , 27, 649-652	3.3	25
51	Outcome of second kidney transplantation in patients with previous post-transplantation Kaposi's sarcoma: A French retrospective study. <i>Clinical Transplantation</i> , 2017 , 31, e13091	3.8	3
50	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
49	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
48	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2017 , 167, 683-684	8	43
47	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>Oncolimmunology</i> , 2016 , 5, 1136045	7.2	18
46	Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11073-11083	7.2	11083

45	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9508-9508	2.2	6
44	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9556-9556	2.2	1
43	Bayesian individual exposure estimation of dabrafenib alone or in combination with trametinib in mutated-BRAF V600E metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14105-e14105	2.2	1
42	Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21056-e21056	2.2	
41	Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. <i>PLoS ONE</i> , 2016 , 11, e0149873	3.7	16
40	Pigmented Bowen's disease presenting with a "starburst" pattern. <i>Dermatology Practical and Conceptual</i> , 2016 , 6, 47-49	1.5	0
39	Anti-PD1-induced collagenous colitis in a melanoma patient. <i>Melanoma Research</i> , 2016 , 26, 308-11	3.3	66
38	ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. <i>EMBO Molecular Medicine</i> , 2016 , 8, 1143-1161	12	78
37	Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1302-1305	4.3	1
36	Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. <i>European Journal of Cancer</i> , 2016 , 60, 179-89	7.5	39
35	Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. <i>Chest</i> , 2016 , 149, e133-6	5.3	107
34	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1374-1385	21.7	818
33	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016 , 40, 466-473	5.8	22
32	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
31	Usual-type vulvar intraepithelial neoplasia: report of a case and its dermoscopic features. <i>International Journal of Dermatology</i> , 2016 , 55, e621-e623	1.7	3
30	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
29	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
28	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. <i>European Journal of Dermatology</i> , 2015 , 25, 36-44	0.8	24

27	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015 , 51, 2396-403	7.5	170
26	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	4.0	926
25	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 102-102	2.2	2
24	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9007-9007	2.2	37
23	Prognostic value of BRAFV600 mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9037-9037	2.2	1
22	Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600mut melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9072-9072	2.2	1
21	EMMPRIN/CD147 as a novel independent prognostic biomarker in melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20027-e20027	2.2	1
20	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20062-e20062	2.2	1
19	A randomized, open label, multicenter comparative phase II trial of ipilimumab after isolated limb perfusion (ILP), versus ILP alone in patients with in-transit metastases melanoma stage IIIB and IIIC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20107-e20107	2.2	
18	Mechanisms of elevated serum creatinine in patients receiving vemurafenib for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20022-e20022	2.2	
17	First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2555-2555	2.2	
16	Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20113-e20113	2.2	
15	BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. <i>Melanoma Research</i> , 2014 , 24, 415-8	3.3	18
14	TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1675-1685	4.3	31
13	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1056-64	14.4	146
12	Ipilimumab-induced acute severe colitis treated by infliximab. <i>Melanoma Research</i> , 2013 , 23, 227-30	3.3	100
11	Personal melanoma risk awareness versus intrinsic risk.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9069-9069	2.2	
10	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 66	3	45

9	Sun exposure profile in the French population: Results of the EDIFICE melanoma survey.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1566-1566	2.2	
8	Comparison of sun protection modalities in parents and children.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8601-8601	2.2	
7	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy-FDG-PET/CT. <i>PET Clinics</i> , 2011 , 6, 9-25	2.2	4
6	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396
5	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
4	Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. <i>Clinical Cancer Research</i> , 2010 , 16, 3288-95	12.9	105
3	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
2	Human herpesvirus 8. <i>Cancer Treatment and Research</i> , 2009 , 146, 169-88	3.5	3
1	Infliximab for hidradenitis suppurativa: report of seven consecutive patients. <i>Experimental Dermatology</i> , 2008 , 15, 482-482	4	1